Litcius/Paper detail

Curative high‐dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure

Arnaud Beddok, C. Saint-Martin, S. Krhili, C. Ala Eddine, Laurence Champion, A. Chillès, F. Goudjil, S. Zefkili, M. Amessis, D. Peurien, O. Choussy, Christophe Le Tourneau, R. Dendale, Irène Buvat, G. Créhange, Valentin Calugaru

2022Head & Neck15 citationsDOI

Abstract

PURPOSE: To analyze outcomes of patients treated with curative reirradiation (reRT), with intensity-modulated radiation therapy (IMRT) or proton therapy (PT) for recurrent head and neck squamous cell carcinoma (HNSCC). MATERIALS: Among the 55 patients reirradiated for head and neck cancer from 30/08/2012 to 08/04/2019, 23 had HNSCC and received IMRT (52.2%) or PT (47.8%) at a median maximum dose to the CTV of 66 Gy. RESULTS: After a median follow-up of 41.3 months, 18 patients developed a locoregional recurrence (LR), of which eight (44.4%) occurred within the previously reirradiated volume. Two-year locoregional failure-free survival and overall survival were 18.3%[95%CI:7.1%-47.1%] and 42.5%[95%CI:26.2%-69.1%], respectively. Disease-free survival was significantly longer in the PT group (p = 0.031). Main late grade ≥2 toxicities were dysphagia and trismus. CONCLUSION: Curative reRT in HNSCC is possible for selected cases, but the LR rate in the irradiated field and the risk of toxicity grade ≥2 remain high.

Topics & Concepts

MedicineTrismusHead and neck cancerDysphagiaRadiation therapyHead and neck squamous-cell carcinomaProton therapyOncologyChemoradiotherapyInternal medicineRadiologySurgeryHead and Neck Cancer StudiesEsophageal Cancer Research and TreatmentHead and Neck Surgical Oncology
Curative high‐dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure | Litcius